Jane Morgan Management
Archer Materials Limited (“Archer”, the “Company”) (ASX:AXE) is pleased to announce that the
Company’s patent application (“International Patent Application”) filed under the Patent
Cooperation Treaty (“PCT”) to protect and commercialise its graphene biosensor technology
intellectual property, has been formally acknowledged as received by the World Intellectual
Property Organization (“WIPO”).
Acknowledgement of receipt by WIPO of Archer’s International PatentApplication successfully
concludes the PCT application lodgement process, and importantly, confirms the International
Patent Application is formally compliant with the PCT prosecution procedure and has met the
deadline to avoid abandonment of the application†.
concludes the PCT application lodgement process, and importantly, confirms the International
Patent Application is formally compliant with the PCT prosecution procedure and has met the
deadline to avoid abandonment of the application†.
Archer’s graphene-based biosensor technology is unique and has the potential to positively disrupt the global medtech industry. There are very few materials in existence that can be used to perform biosensing rapidly and accurately for human health diagnostics. At Archer, we are developing a graphene-based biosensor device that, if successful, will allow for rapid, highly sensitive, portable testing for in-vitro diagnostics.
The global biosensor market revenue is expected to grow to US$27
billion by 20221
. There is a global need for healthcare to become
cheaper, efficient and more accessible. The key driving factors of
growth are ageing populations in North America, Asia and Europe.
Europe is the largest contributor in the printed sensor market.
Biosensors form part of the growing A$300+ billion revenue global
biotechnology industry.
billion by 20221
. There is a global need for healthcare to become
cheaper, efficient and more accessible. The key driving factors of
growth are ageing populations in North America, Asia and Europe.
Europe is the largest contributor in the printed sensor market.
Biosensors form part of the growing A$300+ billion revenue global
biotechnology industry.
With a low industry concentration, large
companies use strategic acquisitions to expand their market share
and access crucial intellectual property describing products that are
commercially viable.
Over 75% of biotechnology businesses are located in Europe and
North America. Approximately 30% of costs in the industry are
related to materials, and the margin in the industry is approximately
20%-30%.
Australia has a critical mass of expertise in biotechnology and is at
the forefront of the industry.
companies use strategic acquisitions to expand their market share
and access crucial intellectual property describing products that are
commercially viable.
Over 75% of biotechnology businesses are located in Europe and
North America. Approximately 30% of costs in the industry are
related to materials, and the margin in the industry is approximately
20%-30%.
Australia has a critical mass of expertise in biotechnology and is at
the forefront of the industry.
About Archer
A materials technology company developing materials in quantum computing, biotechnology,
and lithium-ion batteries, and exploring for minerals in Australia. The Company has strong
intellectual property, broad-scope mineral tenements, world-class in-house expertise, a diverse
advanced materials inventory, and access to over $300 million of R&D infrastructure.
and lithium-ion batteries, and exploring for minerals in Australia. The Company has strong
intellectual property, broad-scope mineral tenements, world-class in-house expertise, a diverse
advanced materials inventory, and access to over $300 million of R&D infrastructure.
https://www.wipo.int/pct/en/faqs/faqs.html
/Public Release.
